🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Tackling diversity in HER2-positive breast cancer: biological and clinical implications” Tomás Pascual on #HER2DX pCR score and drug response at Accademia Medicina #HER2DX is the world’s first diagnostic test specifically for HER2+ #breastcancer More info: ow.ly/sMFl50POgSO

On #WorldBreastCancer Day, we reiterate our commitment to innovation and finding answers for patients; this is what guides our daily work. #BreastCancerAwarenessMonth #breastcancer #precisiononcology #HER2DX

Very encouraging results from the #HER2DX analysis of PHERGain. HER2DX-pCR score was significantly associated with pCR rates and eight out of nine patients experiencing metastatic progression had HER2DX high risk disease (❗️). Deserved more than a poster presentation IMO. #ESMO23

More evidence of clinical utility of #HER2DX for patients with esrly-stage HER2-positive #breastcancer

Dr Javier Cortes MD PhD on PHERGain study explaining our collaboration with MEDSIR #HER2DX #breastcancer #precisiononcology #ESMO23

#SABCS23 | Poster PO3-16-03 | Investigating #HER2DX genomic assay concordance within HER2-positive #breastcancer. Fara Brasó Maristany Ada Waks Sara Tolaney Otto Metzger Polyak Lab Laia Paré Brunet Guillermo Villacampa @prat_aleix Esther Sanfeliu Ana Vivancos

🌟 Merry Christmas and Happy Holidays! 🎄 #precisiononcology #HER2DX #DNADX

Our CSO & co-founder, @prat_aleix received the National Research Award "Doctores Diz Pintado" His exceptional work, including our groundbreaking test #HER2DX, has earned him this prestigious honor. Read about his achievements! 👉🏻 ow.ly/aFFX50QuMxr #precisiononcology

HER2DX to undergo first prospective trial in 7 🇪🇺 countries, supported by a 8M Horizon Europe grant. Congrats to the REVEAL GENOMICS team and co-PIs Tomás Pascual & Olga Martínez-Sáez for initiating this important effort! biospace.com/article/releas…

Introducing the DEFINITIVE project: #HER2DX first prospective trial, led by IDIBAPS, conducted across 44 hospitals in a total of 7 European and associated countries. funded by European Commission’s key funding program for research and innovation👉🏻 ow.ly/bskq50QJs55

This photo doesn't capture everyone, but it offers a glimpse into the remarkable women on our team. Each day, we passionately work to enhance and improve the lives of patients with #breastcancer Let’s build a more equal and just world! #InternationalWomensDay #WomensDay #IWD2024

Poster 12P - #ESMOBreast24 Updated findings from the first prospective #HER2DX clinical decision impact study on early-stage #HER2+ #breastcancer Olga Martínez-Sáez 👉🏻#HER2DX influenced clinical management in early stages of HER2+, increasing physicians' confidence

Poster 74P - #ESMOBreast24 Assessing the Implementation of the #HER2DX Genomic Test in a Real-World Setting for HER2+ #breastcancer Juanmi Cejalvo badamo 👉🏻 #HER2DX is being used across multiple scenarios. The #HER2DX scores provides new insights for patients.

⭐️⭐️⭐️⭐️⭐️We are proud to have one of the best among us. Our CSO & co-founder @prat_aleix has been recognized by Forbes_es as one of the 100 best doctors in Spain. (Article in Spanish) ow.ly/51W350T9Jh2 #precisiononcology #HER2DX

#HER2DX makes its first appearance at #ESMO24! Dr Barbara Pistilli #precisiononcology #breastcancer #ESMO2024

🎉 Celebrating 4 amazing years today! This milestone is just the beginning, thanks to our visionary leadership, committed team, and everyone who trusts us. We are dedicated to transforming cancer care to benefit patients. 🚀 #breastcancer #HER2DX #DNADX #TNBCDX

📢Development and validation of #TNBCDX a new genomic biomarker for early-stage triple-negative breast cancer with an without pembrolizumab. Published in Annals of Oncology annalsofoncology.org/article/S0923-… @prat_aleix Vall d’Hebron Institute of Oncology (VHIO) Laia Paré Brunet Fara Brasó Maristany REVEAL GENOMICS

On this day, we reaffirm our commitment to advancing research, innovation, and #precisiononcology. Every breakthrough brings us closer to better outcomes for #patients. #PrecisionOncology #Innovation #BreastCancerAwarenessMonth #HER2DX #DNADX #TNBCDX

Remarkable Milestones! 🎉 #HER2DX is on a roll, continuously adding valuable clinical evidence data! Here’s everything we’ve achieved so far—and we’re just getting started! Stay tuned for more advancements! 🚀 #HER2+ #precisiononology #breastcancer More: ow.ly/YKZm50TV7QN

Our work isn’t just about innovation—it’s about impact. We are dedicated to developing cutting-edge diagnostic tools that help define the best therapeutic options for patients with cancer, helping them receive the most effective treatment. #WorldCancerDay #precisiononcology